Switching therapy from variable-dose multiple pill to fixed-dose single-pill combinations of angiotensin II receptor blockers and thiazides for hypertension

Clinical and Experimental Hypertension

Volumn 33, Issue 5, 2011, Pages 309-315

  Sakima, Atsushi ^a   Ohshiro, Katsuhiko ^a   Nakada, Seigo ^b   Yamazato, Masanobu ^a   Kohagura, Kentaro ^a   Nakamoto, Minori ^a   Tana, Takeshi ^c   Ohya, Yusuke ^a  

^a UNIVERSITY OF THE RYUKYUS   (Japan)

^b Keiaikai Chibana Clinic   (Japan)

^c Shuri Jokamachi Clinic Daiichi   (Japan)

Author keywords

Adherence; Combination therapy; Hydrochlorothiazide; Hypertension; Losartan

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEMOGLOBIN A1C; HYDROCHLOROTHIAZIDE PLUS LOSARTAN; INDAPAMIDE; LOSARTAN; MEFRUSIDE; OLMESARTAN; TELMISARTAN; TRICHLORMETHIAZIDE; URIC ACID; VALSARTAN;

ADULT; AGED; ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE REGULATION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIABETES MELLITUS; DIZZINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GLOMERULUS FILTRATION RATE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; HYPOTENSION; JAPANESE; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PATIENT SATISFACTION; SINGLE BLIND PROCEDURE; SINGLE DRUG DOSE; URIC ACID BLOOD LEVEL;

AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DRUG COMBINATIONS; FEMALE; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; JAPAN; LOSARTAN; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PATIENT SATISFACTION; SODIUM CHLORIDE SYMPORTER INHIBITORS;

EID: 79960949149     PISSN: 10641963     EISSN: 15256006     Source Type: Journal    
DOI: 10.3109/10641963.2010.549260     Document Type: Article

References (28)

1. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW,Materson BJ, Oparil S, Wright JT Jr, Roccella EJ. National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. JAMA. 2003;289:2560-2572.
2. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Boudier HA, Zanchetti A. ESH-ESC Task Force on the Management of Arterial Hypertension. 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens 2007;25:1751-1762. (Pubitemid 47356612)
3. Ogihara T, Kikuchi K, Matsuoka H, Fujita T, Higaki J, Horiuchi M, Imai Y, Imaizumi T, Ito S, Iwao H, Kario K, Kawano Y, Kim-Mitsuyama S, Kimura G, Matsubara H, Matsuura H, Naruse M, Saito I, Shimada K, Shimamoto K, Suzuki H, Takishita S, Tanahashi N, Tsuchihashi T, Uchiyama M, Ueda S, Ueshima H, Umemura S, Ishimitsu T, Rakugi H. Japanese Society of Hypertension Committee. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Hypertens Res 2009;32:3-107.
4. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet 2005;365:217-223. (Pubitemid 40138015)
5. Wolf-Maier K, Cooper RS, Kramer H, Banegas JR, Giampaoli S, Joffres MR, Poulter N, Primatesta P, Stegmayr B, Thamm M. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 2004;43:10-17. (Pubitemid 38031904)
6. Mori H, Ukai H, Yamamoto H, Saitou S, Hirao K, Yamauchi M, Umemura S. Current status of antihypertensive prescription and associated blood pressure control in Japan. Hypertens Res 2006;29:143-151.
7. Schroeder K, Fahey T, Ebrahim S. How can we improve adherence to blood pressure-lowering medication in ambulatory care? Systematic review of randomized controlled trials. Arch Intern Med 2004;164:722-732. (Pubitemid 38478694)
8. Burnier M. Medication adherence and persistence as the cornerstone of effective antihypertensive therapy. Am J Hypertens 2006;19:1190-1196. (Pubitemid 44633590)
9. Ruilope LM, Burnier M, Muszbek N, Brown RE, Keskinaslan A, Ferber P, Harms G. Public health value of fixed-dose combinations in hypertension. Blood Pres 2008;1(suppl):5-14.
10. Bangalore S, Kamakakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007;120:713-719. (Pubitemid 47176510)
11. Taylor AA, Shoheiber O. Adherence to antihypertensive therapy with fixed-dose amlodipine besylate/benazepril HCl versus comparable component-based therapy. Congest Heart Fail 2003;9:324-332.
12. Gerbino PP, Shoheiber O. Adherence patterns among patients treated with fixed-dose combination versus separate antihypertensive agents. Am J Health Syst Pharm 2007;64:1279-1283. (Pubitemid 47216196)
13. Brixner DI, Jackson KC II, Sheng X, Nelson RE, Keskinaslan A. Assessment of adherence, persistence, and costs among valsartan and hydrochlorothiazide retrospective cohorts in free- and fixed-dose combinations. Curr Med Res Opin 2008;24:2597-2607.
14. Benedict CR. Safe and effective management of hypertension with fixed-dose combination therapy: focus on losartan plus hydrochlorothiazide. Int J Clin Pract 2000;54:48-54. (Pubitemid 30088761)
15. Enomoto A, Kimura H, Chairoungdua A, Shigeta Y, Jutabha P, Cha SH, Hosoyamada M, Takeda M, Sekine T, Igarashi T, Matsuo H, Kikuchi Y, Oda T, Ichida K, Hosoya T, Shimokata K, Niwa T, Kanai Y, Endou H. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature 2002;23:447-452. (Pubitemid 34563537)
16. Shahinfar S, Simpson RL, Carides AD, Thiyagarajan B, Nakagawa Y, Umans JG, Parks JH, Coe FL. Safety of losartan in hypertensive patients with thiazide-induced hyperuricemia. Kidney Int 1999;56:1879-1885. (Pubitemid 29518189)
17. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A. Collaborators developing the Japanese equation for estimated GFR. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009;53:982-992.
18. Burnier M. Medication adherence and persistence as the cornerstone of effective antihypertensive therapy. Am J Hypertens 2006;19:1190-1196. (Pubitemid 44633590)
19. Krousel-Wood M, Thomas S, Muntner P, Morisky D. Medication adherence: a key factor in achieving blood pressure control and good clinical outcomes in hypertensive patients. Curr Opin Cardiol 2004;19:357-362. (Pubitemid 38916494)
20. Gupta AK, Arshad S, Poulter NR. Compliance, Safety, and Effectiveness of Fixed-Dose Combinations of Antihypertensive Agents: A Meta-Analysis. Hypertension 2010;55: 399-407.
21. Carter BL, Ernst ME, Cohen JD. Hydrochlorothiazide versus chlorthalidone: evidence supporting their interchangeability. Hypertension 2004;43:4-9. (Pubitemid 38031903)
22. Naritomi K, Fujita T, Ito S, Ogihara T, Shimada K, Shimamoto K, Tanaka H, Yoshiike N. Efficacy and safety of long-term losartan therapy demonstrated by a prospective observational study in Japanese patients with hypertension: The Japan hypertension evaluation with angiotensin II antagonist losartan therapy (J-HEALTH) Study. Hypertens Res 2008;31:295-304. (Pubitemid 351461110)
23. Bakris GL, Toto RD, McCullough PA, Rocha R, Purkayastha D, Davis P. GUARD (gauging albuminuria reduction with lotrel in diabetic patients with hypertension) study investigators. Effects of different ACE inhibitor combinations on albuminuria: Results of the GUARD study. Kidney Int 2008;73:1303-1309.
24. Jamerson K, Weber MA, Bakris GL, Dahlof B, Pitt B, Shi V, Hester A, Gupte J, Gatlin M, Velazquez EJ. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008;359:2417-2428.
25. Abe M, Okada K, Maruyama T, Matsumoto K. Antiproteinuric and blood pressure-lowering effects of a fixed-dose losartan and hydrochlorothiazide combination in hypertensive patients with stage 3 chronic kidney disease. Pharmocotherapy 2009;9:1061-1072.
26. Bakris G, Molitch M, Hewkin A, Kipnes M, Sarafidis P, Fakouhi K, Bacher P, Sowers J; STAR Investigators. Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome. Diabetes Care 2006;29:2592-2597. (Pubitemid 44912184)
27. Franse LV, Pahor M, Di Bari M, Shorr RI, Wan JY, Somes GW, Applegate WB. Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). J Hypertens 2000;18: 1149-1154.
28. Høieggen A, Alderman MH, Kjeldsen SE, Julius S, Devereux RB, De Faire U, Fyhrquist F, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, Chen C, Dahlöf B; LIFE Study Group. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 2004;65: 1041-1049. (Pubitemid 38251080)